The partners said March 3 that the partnership’s main goal is the development of the soft tissue surgery medical devices industry, which lags behind its orthopedic and cardiologic equivalents.
“Having [the Hospital for Endocrine Surgery’s team] in our facility on a regular basis to meet with and collaborate with biologic companies and device manufacturers is expected to speed up their new product development, ultimately resulting in better cure rates and better outcomes,” Five Labs CEO Derek Pupello said in a statement.
The surgeons and Five Labs will also host annual device, biologics and training conferences for all soft tissue surgeons including endocrine surgeons, surgical oncologists and ENT surgeons.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
